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Abstract
Objective—Chronic lung disease is exacerbated by comorbid psychiatric issues and treatment of
depression may improve disease symptoms. We sought to add to the literature as to whether
depression is associated with pulmonary function in healthy adults.
Methods—In 2,551 healthy adults from New York State, USA, we studied the association of
depression via the Center for Epidemiologic Studies Depression scale (CES-D) score and forced
expiratory volume (FEV1) and forced vital capacity (FVC) using general linear models and a cross
sectional design.
Results—We identified statistically significant inverse trends in FEV1, FVC, FEV1% and FVC%
by CES-D category especially in ever smokers and men. When adjusted for covariates, the
difference in FEV1 and FEV1% for smokers with >18.5 lifetime pack years from CES-D score 0-3
to ≥16 (depressed) is approximately 0.25 L and 5.0%; adjusted P for trend are <0.001 and 0.019,
respectively. In men, we also observed statistically significant inverse trends in pulmonary
function with increasing CES-D.
Conclusions—We identified an inverse association of depressive symptoms and pulmonary
function in healthy adults especially in men and individuals with a heavy smoking history. Further
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studies of these associations are essential for the development and tailoring of interventions for the
prevention and treatment of chronic lung disease.
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INTRODUCTION
The relationship between mental health and respiratory health is well recognized [1-3];
however the direction and exact nature of these complex associations are unknown. While
stressful stimuli can have short-term and measurable influence specifically on the airways
[3-5]; less is known about the long-term influence of mental health on airways, pulmonary
function, and the complex phenotypes of asthma and COPD.
In individuals already diagnosed with chronic lung disease, there is evidence that depressive
symptoms in particular are a direct result of chronic lung disease. Here, biologic changes
due to the disease process may be implicated in development of depressive symptoms.
Depression may however also play an earlier role in the disease process, detectable before
the onset of chronic lung disease, but also may be intrinsically linked with smoking behavior
[6]. Improving both the psychological and physical well-being of individuals already
diagnosed with chronic lung disease may potentially improve quality of life and outcomes
[7-9].
To date, there are no large and comprehensive studies that have reported on the association
of mental health and pulmonary function before diagnosis of chronic lung disease in
attempts to tease out the effects of smoking. Therefore, we examined the association of
pulmonary function and depressive symptoms measured via CES-D score in a sample of
adults never diagnosed with chronic lung disease. Due to the association of depression and
smoking, we hypothesized a priori that smoking modifies the association of depressive
symptoms and reduced pulmonary function.
METHODS
Study population
As previously described [10], we randomly selected participants aged 35-79 from the
general population in Erie and Niagara counties in western New York State between 1996
and 2000 for a cross-sectional study, with the goal of investigating several potential
determinants of pulmonary function. Of our original sample (n=4,065), we excluded
individuals who had missing or unacceptable pulmonary function tests (n=1,049), missing
CES-D questionnaire (n=91), and those who have ever been diagnosed by a physician with
fibrosis (n=8) or chronic airflow limitation (asthma, COPD, chronic bronchitis or
emphysema) (n = 366), resulting in 1,276 men and 1,275 women for analysis. The study was
approved by the University at Buffalo Health Sciences Institutional Review board and all
participants provided written informed consent.
Pulmonary Function Tests
Trained personnel performed spirometry according to American Thoracic Society
recommendations as previously reported [11]. We first performed two to three slow practice
maneuvers followed by at least three but no more than eight maneuvers, and used the best of
three acceptable maneuvers for study. Approximately 6.9% (n=223) of the sample who had
a pulmonary function test performed was excluded from this study due to unacceptable tests.
Ochs-Balcom et al. Page 2
Psychosom Med. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
To obtain percent predicted values for FEV1 and FVC (FEV1% and FVC%) we used
NHANES data to adjust for sex, age, height and race/ethnicity [12].
Center for Epidemiologic Studies Depression Scale Questionnaire (CES-D)
The CES-D questionnaire measures self-reported depressive symptoms experienced by a
person during the previous week [13]. Each question is scored 0-3 based on the person's
response, resulting in a possible score range of 0-60. The person is considered depressed if
his or her score is ≥16. This screening tool has been extensively evaluated for validity and
reliability [14, 15].
Measurement of other relevant covariates
During the study visit, we collected data on demographics, medical history and an array of
other behavior variables including lifetime smoking data. A computer-assisted interview was
used to assess cumulative lifetime exposure to smoking (pack-years); from this, we
classified individuals as current, former or never smokers (less than 100 cigarettes smoked
during lifetime). Physical measurements were taken using standard protocol and include
height, weight, waist circumference and hip circumference. For abdominal height,
interviewers used a Holtain-Kahn abdominal caliper and measured the sagittal diameter of
the participant in the supine position [16]. Serum beta cryptoxanthin was measured by high-
pressure liquid chromatography on a Shimadzu LC-7A device with SPD-M6A photodiode
array (Shimadzu Scientific Instruments, Inc., Braintree, MA) and expressed as μg/ml [17].
An automated differential blood cell count was determined at the Kaleida/Millard Fillmore
Hospital Center for Laboratory Medicine in Buffalo, New York, using a Coulter Counter
(Beckman Coulter, Inc., Fullerton, CA).
Statistical analyses
We computed descriptive statistics for all relevant variables to characterize the sample, and
used student's t-tests and chi-squared tests to examine differences between measurements
collected for men and women as appropriate. Spearman correlation coefficients were
estimated to examine linear associations between continuous measures of CES-D and
pulmonary function measures.
We analyzed trends in FEV1, FVC, FEV1%, and FVC% across four strata defined by CES-
D score (0-3, 4-8, 9-15, and ≥16) using general linear models that were adjusted for the
following covariates as appropriate because they are associated with pulmonary function in
this sample: age, sex, height, race/ethnicity (white, African American, and Hispanic),
education, smoking status (ever/never), lifetime number of pack-years, abdominal height
(cm), and serum beta-cryptoxanthin (positively associated with pulmonary function), and
eosinophil count for FEV1 and FEV1% only (inversely associated with FEV1 [17-19]. Since
FEV1% and FVC% predicted values are already adjusted for age, sex, height and race/
ethnicity, we did not adjust for these covariates in these respective models. We assessed
significance using P-values for trend where CES-D is included in linear models as a
continuous variable (instead of categories), where any P-value <0.050 was considered
statistically significant.
We decided a priori to examine the association by stratifying by smoking status and sex to
analyze potential effect modification of the association of pulmonary function and
depressive symptoms by smoking status and sex. To test interaction hypotheses, we created
multiplicative interaction terms for lifetime pack years of smoking × CES-D score and sex ×
CES-D score. For tests of multiplicative interaction, we considered P-values <0.10
statistically significant. For all analyses, we used the SAS statistical software package (SAS,
version 9.2; SAS; Cary, NC).
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RESULTS
Table 1 shows descriptive characteristics of the study population, including means for CES-
D and pulmonary function measures stratified by sex. The mean age of participants in our
sample is 57.3 years (standard deviation (SD)=11.5 years) and 60.4 years (SD=11.9 years)
for women and men, respectively. Approximately 7% of our sample is African-American
and 0.6% is Hispanic. FEV1 and FVC values are higher for men; however in comparison to
US reference values (based on the average level of lung function observed in healthy
nonsmoking persons of the same age, sex, height and race/ethnicity), FEV1% predicted and
FVC% predicted values are higher in women (P<0.001). More women in our sample are
current smokers, but men have a higher lifetime exposure to cigarettes as measured by pack
years (P<0.001). Mean BMI values for women and men are 27.8 kg/m2 (SD=6.0 kg/m2) and
28.5 kg/m2 (SD=4.5 kg/m2), respectively. Women in this sample are more likely to have
CES-D scores ≥16, indicative of depression; 13.8% of women had scores ≥16 versus 10.5%
of men. Thirty nine percent of women and 45% of men had CES-D scores in the lowest
category (0-3). Spearman correlation coefficients between CES-D score and pulmonary
function values were approximately −0.18 for FEV1 and FVC, and −0.07 for both FEV1%
and FVC%, and all are statistically significant (data not shown).
Table 2 shows trends in adjusted mean FEV1 and FVC by CES-D category in ever smokers,
split according to the median value of lifetime pack years of smoking of 18.5 pack years,
and never smokers separately. The interaction term for lifetime pack years × CES-D is
statistically significant for FEV1 (interaction P-value=0.052) only. In both smoking groups,
the inverse trends in FEV1, FVC and FEV1% were statistically significant; the lowest values
of pulmonary function are observed in the groups with the highest values of CES-D (all P-
for trend <0.035). We observed marginally significant trends in FVC% in ever smokers; P-
values for trend were approximately 0.050 in both groups. In never smokers, we report a
statistically significant inverse trend in FVC (L) only (P-for trend=0.038) across strata of
CES-D scores.
With regard to magnitude of differences in the lowest versus the highest categories of CES-
D, in the group of smokers with more than 18.5 lifetime pack years, the difference in FEV1
between CES-D score 0-3 and ≥16 (depressed) was 0.25 L, the difference in FVC was 0.23
L, and the FEV1% difference was 5.0% (Table 2, Model 2). For smokers with less than 18.5
lifetime pack years of smoking, the differences were similar in magnitude; we observed a
0.19 L difference in FEV1, a 0.20 difference in FVC, and a 6% difference in FEV1%
between the highest and lowest categories defined by CES-D score.
When we modeled the continuous CES-D variable (instead of using four categories) in
linear models predicting differences in pulmonary function, we observed beta coefficients of
−0.01 (standard error=0.004) for the models of FEV1 and FVC analyzed in liters. These
estimates suggest that for every unit increase in CES-D score, FEV1 and FVC is
approximately 0.01 L lower. Similarly, in the FEV1 percent predicted model, we estimated a
beta coefficient of −0.29 (standard error=0.12), suggesting that for every unit increase in
CES-D score, FEV1% is approximately 0.29% lower (data not shown).
The interaction between sex and CES-D score was significant for FEV1 (P=0.003), FVC
(P=0.008) and FEV1% (P=0.048); therefore we present results stratified by sex in Table 3.
TableIn men, inverse trends in the fully-adjusted models for all measures of pulmonary
function analyzed were statistically significant (all P for trend<0.004), with differences
between CES-D category 0-3 and ≥16 category of approximately 0.20 L. The difference in
FEV1% from CES-D category 0-3 and ≥16 category was 4.4%. In women, FVC (L) was the
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only pulmonary function measure that reached statistical significance for linear trends across
CES-D categories (P for trend=0.022).
DISCUSSION
We investigated the relation of pulmonary function measures and depressive symptoms
measured by CES-D score in a cross-sectional study of healthy adults. Our results suggest
that ex sex independently modifies the association of FEV1, FVC and FEV1%; we observed
the strongest inverse associations between depressive symptoms and pulmonary function in
men. The statistically significant interaction we observed for FEV1 according to categories
of lifetime pack years along with the differences in the differences in FEV1 across CES-D
categories suggests that depression is particularly associated with FEV1 in those with more
than 18 pack years of smoking. Men and smokers with more than 18.5 pack years and the
highest CES-D scores had the lowest FEV1, FVC, FEV1% and FVC% values, all of which
reached statistical significance with the exception of FVC%. Our findings support our a
priori hypothesis that depressive symptoms are inversely associated with pulmonary
function in healthy adults. However, in our sample, there were no associations of pulmonary
function and depressive symptoms among women and weaker evidence of an association
with FVC among never smokers and in women.
Candidate biologic mechanisms for the depression-airway reactivity association are
currently under study and include inflammatory and immune as well as cholinergic/vagal
mechanisms [5, 20]. Whether these mechanisms, largely explored in the context of adult and
childhood asthma and reflective of short-term response, translate to long-term periods of
depression is yet to be explored.
Smoking plays an important role in this association of CES-D and FEV1, since we observed
the largest differences in FEV1 across CES-D categories in smokers compared to never
smokers. Depressive symptoms may be related to decreased pulmonary function due to
smoking behavior [21]. Individuals with depression are more likely to smoke and smoking
behavior has been linked to chronic pulmonary diseases and decreased pulmonary function
[7, 22]. According to a nationally representative survey, the prevalence of smoking among
the mentally ill is nearly double that of the general United States population, where nearly
one-third of smokers had met ICD-10 criteria for a mental disorder [23]. Our finding of
smoking status as a statistically significant effect modifier (for FEV1) implicates smoking,
and this is not surprising given that smoking is associated with both pulmonary function and
mental health.
To our knowledge, five large epidemiologic studies to date have attempted to examine
associations between lung function and depressive symptoms. The first two studies focused
on risk and prevalence of depression in the presence of chronic lung disease (versus
quantitative pulmonary function measures). Findings from Bisschop et al suggest that
chronic lung disease is associated with increased risk of depression over 3 years of follow-
up; however they reported no association of incident lung disease and CES-D [2]. These
findings may suggest that the association of chronic lung disease and depression is more
important over a longer time period, which is in agreement with our evidence for an
association in “healthy” adults of depression and pulmonary function measures earlier in the
CLD disease process. Another study showed that chronic lung disease is associated with
significantly higher prevalence of depressed mood measured via CES-D [24].
The third, a study of NHANES data, reported an association of obstructive lung function and
worse mental health status; however this study did not have the data available to examine
smoking in the relationship between lung function and mental health [25]. Two subsequent
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studies have assessed lung function and mental health [26, 27] but only one was performed
in a sample representative of the general population [27]; this study reported that asthma and
chronic bronchitis were associated with mental health problems but objective lung function
assessed by spirometry was only associated with anxiety [27]. The final study was
conducted in a population of adults who had served in Vietnam [26]; generalized anxiety
disorder and major depressive disorder was associated with poor lung function; however,
only generalized anxiety disorder remained significant after adjustment for covariates.
Other investigators have reported an increased prevalence of depression in COPD patients
[7, 28] and that symptoms of depression are associated with decreased pulmonary function
values, specifically FEV1 [8]. Similar to our study sample where we have a higher
prevalence of depression reported among women never diagnosed with COPD, one study
reported that female COPD patients were more likely to be depressed and exhibit depressive
symptoms than men [21, 29, 30], which indicates that women may be at even greater risk of
depression in the context of COPD. In addition, among smokers, women were more likely to
meet the criteria for mental illness than men [23]. We observed an interaction between sex
and CES-D, which may be due to the smaller differences between the lowest and highest
CES-D categories in women. While the trends in women did not reach statistical
significance for FEV1 or FEV1%, the trends for FVC (L) were statistically significant. This
finding may be due to the increased prevalence of depressive symptoms in women in our
sample.
Our study differs from previous studies on this topic because many previous studies focused
on participants diagnosed with COPD [8, 21, 29-31] whereas we focused on a large sample
of healthy adults who have never been diagnosed with chronic lung disease. In addition,
sample size is a limitation for many previous studies, with most studies including fewer than
500 participants. Another difference between our study and others in the literature is the
measurement of depressive symptoms. We used the CES-D questionnaire, whereas other
measurement tools used in previous literature include the Beck Depression Inventory [29],
the Hospital Anxiety and Depression Scale [30, 32] or the 15-item Geriatric Depression
Score [8]. The CES-D questionnaire has been used across all age groups and has proven to
be valid and reliable for use in the general population [14, 15].
A major strength of our study lies in the available study population, a large sample of
healthy adults that includes a detailed ascertainment of lifetime smoking history.
Standardized anthropometric and pulmonary function measures and the use of the validated
CES-D questionnaire to assess depressive symptoms provide much strength to this study.
With these standardized quantitative measures, we had the ability to adjust for a number of
factors that are known to influence pulmonary function.
Previously, no study has used a large, population-based sample to study the association
between depression and pulmonary function, nor has there been a focus on healthy
individuals never diagnosed with chronic lung disease. By studying this association in
healthy individuals, we are better able to understand associations between depression and
pulmonary function prior to diagnosis with chronic lung disease. This understanding may
provide a novel intervention opportunity with the aim of reducing pulmonary function
decline or progression of chronic lung disease before irreversible manifestations occur.
The cross-sectional nature of our study is a limitation because of the lack of temporality. In
addition, our sample may contain some individuals with undiagnosed chronic lung disease,
which may potentially strengthen the inverse associations seen between pulmonary function
and depressive symptoms. In our study sample, 382 of 2,551 (15%) had an FEV1/FVC of
70% or lower. In sensitivity analyses where we excluded individuals with a FEV1/FVC
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<70% in an attempt to exclude individuals with undiagnosed pulmonary disease, the results
are essentially unchanged. The association of CES-D is still most significant for individuals
who have ever smoked and the FEV1 difference between the lowest CES-D category (0-3)
and highest (≥16) is approximately 0.23 L and 5.6%. Interestingly, when individuals with
FEV1/FVC <70% are excluded, all of the trends in the association of CES-D and pulmonary
function become more statistically significant in women (data not shown). In addition, since
spirometry is effort-dependent, depressed participants may not have performed the tests with
maximum effort, which may contribute to the observed associations.
The fact that the associations between CES-D and pulmonary function remain even after
adjustment for abdominal obesity, a confounding variable, further supports the merit of an
association; however this association requires further study.
Participants with low pulmonary function values may be more likely to indicate
experiencing a symptom of depression that is actually a result of underlying disease [31, 33,
34], making interpretation of findings difficult. Our aforementioned sensitivity analysis that
excluded individuals with FEV1/FVC <70% however further supports the hypothesis that
the association of CES-D and pulmonary function may be mitigated through smoking
behavior rather than the disease process itself.
Future studies into these associations should be longitudinal in design so the mechanism of
chronic lung disease progression can be determined in regards to smoking behavior and
depression. We know that there is a causal relationship between smoking and COPD [7], but
the role of depression in this etiological relationship has never been sufficiently illustrated.
Is this association a ‘feedback loop’ as others suggest [34] or is depression the underlying
cause of disease in these individuals, predating even smoking behavior?
Overall, our results suggest that depression may play an even earlier role in the chronic lung
disease process, and that sex and smoking play a role. If this association is replicated in
other studies, it would be very interesting to evaluate whether improvement in mental status
would translate into improvement in pulmonary function.
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Table 1
Descriptive Characteristics, Mean (SD) or n (%), of Study Participants in Erie and Niagara Counties, Western
New York State, 1996-2000.
Characteristic Total (n=2,551) Men (n=1,276) Women (n=1,275) P-valuea
Age (yr) 58.8 (11.8) 60.4 (11.9) 57.3 (11.5) <0.001
Age group
    ≤40 170 (6.7) 85 (6.7) 85 (6.7)
    41-50 605 (23.7) 259 (20.3) 346 (27.1)
    51-60 545 (21.4) 229 (18.0) 316 (24.8) <0.001
    61-70 726 (28.5) 385 (30.2) 341 (26.8)
    > 70 505 (19.8) 318 (24.9) 187 (14.7)
Race/ethnicity
    Hispanic 15 (0.6) 10 (0.8) 5 (0.4)
    African American 179 (7.0) 92 (7.2) 87 (6.8) 0.40
    White 2,357 (92.4) 1,174 (92.0) 1,183 (92.8)
Education
    ≤High school/GED 1,068 (42.1) 482 (38.1) 586 (46.2)
    College <4 yrs 725 (28.6) 369 (29.2) 356 (28.1) <0.001
    College ≥4 yrs 742 (29.3) 415 (32.8) 327 (25.8)
Smoking status
    Current 336 (13.2) 157 (12.3) 179 (14.1)
    Former 1,105 (43.5) 657 (51.7) 448 (35.3) <0.001
    Never 1,102 (43.3) 458 (36.0) 644 (50.7)
Lifetime pack-years of smoking 13.24 (19.5) 17.53 (22.2) 8.98 (15.1) <0.001
Lifetime pack-years of smoking among smokers 23.4 (20.8) 27.5 (22.4) 18.2 (17.2) <0.001
BMI (kg/m2) 28.1 (5.3) 28.5 (4.5) 27.8 (6.0) 0.002
Abdominal height (cm) 21.3 (3.5) 22.2 (3.2) 20.3 (3.5) <0.001
Waist circumference (cm) 92.5 (14.6) 99.2 (12.1) 85.8 (13.9) <0.001
CES-D score 7.0 (7.5) 6.5 (7.2) 7.5 (7.7) 0.001
CES-D score category
    0 – 3 1075 (42.1) 574 (45.0) 501 (39.3)
    4 – 8 684 (26.8) 346 (27.1) 338 (26.5) 0.003
    9 – 15 482 (18.9) 222 (17.4) 260 (20.4)
    ≥ 16 310 (12.2) 134 (10.5) 176 (13.8)
FEV1 (L) 2.95 (0.81) 3.32 (0.83) 2.57 (0.57) <0.001
FVC (L) 3.83 (0.99) 4.35 (0.97) 3.30 (0.69) <0.001
FEV1/FVC 0.77 (0.08) 0.76 (0.08) 0.78 (0.07) <0.001
FEV1%
b 99.2 (17.5) 97.3 (18.4) 101.1 (16.3) <0.001
FVC%b 99.1 (15.8) 96.7 (16.1) 101.5 (15.2) <0.001
Abbreviations: CES-D = Center for Epidemiologic Studies Depression scale; FEV1 = forced expiratory volume; FVC = forced vital capacity; SD =
standard deviation.
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aStudent's t-tests or chi-squared tests for differences by sex.
b
FEV1% and FVC% calculated using U.S. reference values [12].
Psychosom Med. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ochs-Balcom et al. Page 12
Ta
bl
e 
2
A
dju
ste
d M
ean
 Le
ve
ls 
of 
Pu
lm
on
ary
 Fu
nc
tio
n b
y P
ack
 Y
ear
s o
f S
mo
kin
g a
nd
 C
ES
-D
 Sc
ore
, M
ean
 (S
E)
, in
 Er
ie 
an
d N
iag
ara
 C
ou
nti
es,
 W
est
ern
 N
ew
Y
or
k 
St
at
e,
 1
99
6-
20
00
.
>
18
.5
 li
fe
tim
e p
ac
k-
ye
ar
s o
f s
m
ok
in
g
≤1
8.
5 
lif
et
im
e p
ac
k-
ye
ar
s o
f s
m
ok
in
g
N
ev
er
 sm
ok
er
s
Pu
lm
on
ar
y 
fu
nc
tio
n
C
ES
-D
 ca
te
go
ry
N
M
od
el
 1
a
M
od
el
 2
b
N
M
od
el
 1
a
M
od
el
 2
b
N
M
od
el
 1
a
M
od
el
 2
b
FE
V
1,
d  
L
0 
– 
3
27
8
2.
85
 (0
.03
)
2.
90
 (0
.04
)
31
0
3.
09
 (0
.03
)
3.
08
 (0
.03
)
48
2
3.
02
 (0
.02
)
3.
02
 (0
.02
)
4 
– 
8
20
0
2.
77
 (0
.04
)
2.
84
 (0
.05
)
17
8
3.
05
 (0
.03
)
3.
08
 (0
.04
)
30
2
3.
02
 (0
.02
)
3.
08
 (0
.03
)
9 
– 
15
13
0
2.
69
 (0
.05
)
2.
70
 (0
.07
)
14
4
3.
01
 (0
.04
)
3.
07
 (0
.05
)
20
3
3.
01
 (0
.03
)
3.
03
 (0
.04
)
≥ 
16
10
5
2.
68
 (0
.06
)
2.
65
 (0
.07
)
88
2.
85
 (0
.05
)
2.
89
 (0
.06
)
11
5
2.
91
 (0
.04
)
2.
96
 (0
.05
)
P-
v
al
ue
 fo
r t
re
nd
<
0.
00
1
<
0.
00
1
<
0.
00
1
0.
01
8
0.
00
8
0.
14
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
05
2
FV
C,
 L
0 
– 
3
27
8
3.
84
 (0
.04
)
3.
92
 (0
.05
)
31
0
3.
93
 (0
.03
)
3.
95
 (0
.04
)
48
2
3.
86
 (0
.02
)
3.
88
 (0
.03
)
4 
– 
8
20
0
3.
76
 (0
.05
)
3.
84
 (0
.06
)
17
8
3.
95
 (0
.04
)
4.
01
 (0
.05
)
30
2
3.
83
 (0
.03
)
3.
91
 (0
.04
)
9 
– 
15
13
0
3.
67
 (0
.06
)
3.
70
 (0
.07
)
14
4
3.
85
 (0
.05
)
3.
93
 (0
.06
)
20
3
3.
83
 (0
.04
)
3.
84
 (0
.05
)
≥ 
16
10
5
3.
71
 (0
.06
)
3.
69
 (0
.08
)
88
3.
67
 (0
.06
)
3.
74
 (0
.08
)
11
5
3.
69
 (0
.05
)
3.
77
 (0
.07
)
P-
v
al
ue
 fo
r t
re
nd
0.
01
4
<
0.
00
1
<
0.
00
01
0.
01
4
0.
00
3
0.
03
8
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
22
FE
V
1%
d,e
0 
– 
3
27
8
94
.0
 (1
.42
)
31
0
10
2.
5 
(1.
10
)
48
2
10
3.
3 
(0.
84
)
4 
– 
8
20
0
91
.4
 (1
.72
)
17
8
10
2.
9 
(1.
43
)
30
2
10
5.
3 
(1.
12
)
9 
– 
15
13
0
88
.5
 (2
.23
)
14
4
10
3.
0 
(1.
64
)
20
3
10
3.
8 
(1.
33
)
≥ 
16
10
5
89
.0
 (2
.51
)
88
96
.5
 (2
.17
)
11
5
10
1.
3 
(1.
81
)
P-
v
al
ue
 fo
r t
re
nd
0.
01
9
0.
03
5
0.
20
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
19
FV
C%
e
0 
– 
3
27
8
97
.0
 (1
.18
)
31
0
10
1.
3 
(1.
03
)
48
2
10
2.
4 
(0.
81
)
4 
– 
8
20
0
94
.5
 (1
.43
)
17
8
10
3.
3 
(1.
35
)
30
2
10
3.
5 
(1.
09
)
9 
– 
15
13
0
92
.8
 (1
.84
)
14
4
10
1.
6 
(1.
54
)
20
3
10
1.
2 
(1.
28
)
≥ 
16
10
5
94
.3
 (2
.08
)
88
96
.8
 (2
.04
)
11
5
99
.7
 (1
.73
)
Psychosom Med. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ochs-Balcom et al. Page 13
>
18
.5
 li
fe
tim
e p
ac
k-
ye
ar
s o
f s
m
ok
in
g
≤1
8.
5 
lif
et
im
e p
ac
k-
ye
ar
s o
f s
m
ok
in
g
N
ev
er
 sm
ok
er
s
Pu
lm
on
ar
y 
fu
nc
tio
n
C
ES
-D
 ca
te
go
ry
N
M
od
el
 1
a
M
od
el
 2
b
N
M
od
el
 1
a
M
od
el
 2
b
N
M
od
el
 1
a
M
od
el
 2
b
P-
v
al
ue
 fo
r t
re
nd
0.
05
2
0.
04
7
0.
06
6
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
68
A
bb
re
vi
at
io
ns
: C
ES
-D
 =
 C
en
te
r f
or
 E
pi
de
m
io
lo
gi
c 
St
ud
ie
s D
ep
re
ss
io
n 
sc
al
e;
 F
EV
1 
=
 fo
rc
ed
 e
xp
ira
to
ry
 v
ol
um
e;
 F
V
C 
= 
fo
rc
ed
 v
ita
l c
ap
ac
ity
; S
E 
= 
sta
nd
ar
d 
er
ro
r.
a M
od
el
 1
: G
en
er
al
 li
ne
ar
 m
od
el
 a
dju
ste
d f
or 
ag
e, 
he
igh
t, r
ace
 an
d s
ex
.
b M
od
el
 2
: G
en
er
al
 li
ne
ar
 m
od
el
 a
dju
ste
d f
or 
Mo
de
l 1
 va
ria
ble
s p
lus
 ab
do
mi
na
l h
eig
ht,
 ed
uc
ati
on
 an
d s
eru
m 
be
ta 
cry
pto
xa
nth
in.
d F
EV
1 
an
d 
FE
V
1%
 w
er
e 
ad
di
tio
na
lly
 a
dju
ste
d f
or 
eo
sin
op
hil
 co
un
t.
e F
EV
1%
 a
nd
 F
V
C%
 w
er
e 
an
al
yz
ed
 w
ith
ou
t a
dju
stm
en
ts 
for
 ag
e, 
sex
, h
eig
ht,
 an
d r
ace
.
f P
-
v
al
ue
s r
ep
re
se
nt
 m
ul
tip
lic
at
iv
e 
in
te
ra
ct
io
n 
te
rm
s f
or
 li
fe
tim
e 
pa
ck
 y
ea
rs
 a
nd
 q
ua
nt
ita
tiv
e 
va
lu
es
 o
f C
ES
-D
 sc
or
e.
Psychosom Med. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ochs-Balcom et al. Page 14
Ta
bl
e 
3
A
dju
ste
d M
ean
 Le
ve
ls 
of 
Pu
lm
on
ary
 Fu
nc
tio
n b
y S
ex
 an
d C
ES
-D
 Sc
ore
 C
ate
go
rie
s, M
ean
 (S
E)
, in
 Er
ie 
an
d N
iag
ara
 C
ou
nti
es,
 W
est
ern
 N
ew
 Y
ork
 St
ate
,
19
96
-2
00
0.
M
al
e
Fe
m
al
e
Pu
lm
on
ar
y 
fu
nc
tio
n
C
ES
-D
 ca
te
go
ry
N
M
od
el
 1
a
M
od
el
 2
b
N
M
od
el
 1
a
M
od
el
 2
b
FE
V
1d
0 
– 
3
57
4
3.
40
 (0
.02
)
3.
45
 (0
.03
)
50
1
2.
59
 (0
.02
)
2.
56
 (0
.02
)
4 
– 
8
34
6
3.
34
 (0
.03
)
3.
45
 (0
.04
)
33
8
2.
57
 (0
.02
)
2.
58
 (0
.03
)
9 
– 
15
22
2
3.
27
 (0
.04
)
3.
37
 (0
.05
)
26
0
2.
56
 (0
.02
)
2.
56
 (0
.03
)
≥ 
16
13
4
3.
11
 (0
.05
)
3.
26
 (0
.06
)
17
6
2.
50
 (0
.03
)
2.
49
 (0
.04
)
P-
v
al
ue
 fo
r t
re
nd
<
0.
00
1
0.
00
1
0.
01
0
0.
05
8
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
00
3
FV
C
0 
– 
3
57
4
4.
42
 (0
.03
)
4.
53
 (0
.03
)
50
1
3.
32
 (0
.02
)
3.
30
 (0
.03
)
4 
– 
8
34
6
4.
35
 (0
.04
)
4.
51
 (0
.05
)
33
8
3.
32
 (0
.02
)
3.
34
 (0
.03
)
9 
– 
15
22
2
4.
30
 (0
.05
)
4.
41
 (0
.06
)
26
0
3.
28
 (0
.03
)
3.
28
 (0
.04
)
≥ 
16
13
4
4.
14
 (0
.06
)
4.
32
 (0
.08
)
17
6
3.
22
 (0
.04
)
3.
21
 (0
.04
)
P-
v
al
ue
 fo
r t
re
nd
<
0.
00
1
<
0.
00
1
0.
01
0
0.
02
2
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
00
8
FE
V
1%
d,e
0 
– 
3
57
4
99
.0
 (0
.86
)
50
1
10
1.
2 
(0.
86
)
4 
– 
8
34
6
98
.7
 (1
.15
)
33
8
10
2.
4 
(1.
08
)
9 
– 
15
22
2
96
.3
 (1
.48
)
26
0
10
2.
2 
(1.
22
)
≥ 
16
13
4
94
.6
 (1
.97
)
17
6
99
.3
 (1
.53
)
P-
v
al
ue
 fo
r t
re
nd
0.
00
4
0.
30
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
04
8
FV
C%
e
0 
– 
3
57
4
98
.9
 (0
.76
)
50
1
10
1.
8 
(0.
82
)
4 
– 
8
34
6
98
.3
 (1
.02
)
33
8
10
3.
3 
(1.
03
)
9 
– 
15
22
2
96
.3
 (1
.31
)
26
0
10
1.
7 
(1.
16
)
≥ 
16
13
4
95
.4
 (1
.75
)
17
6
10
0.
0 
(1.
45
)
P-
v
al
ue
 fo
r t
re
nd
0.
00
4
0.
14
Psychosom Med. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Ochs-Balcom et al. Page 15
M
al
e
Fe
m
al
e
Pu
lm
on
ar
y 
fu
nc
tio
n
C
ES
-D
 ca
te
go
ry
N
M
od
el
 1
a
M
od
el
 2
b
N
M
od
el
 1
a
M
od
el
 2
b
in
te
ra
ct
io
n 
P-
v
al
ue
f
0.
16
A
bb
re
vi
at
io
ns
: C
ES
-D
 =
 C
en
te
r f
or
 E
pi
de
m
io
lo
gi
c 
St
ud
ie
s D
ep
re
ss
io
n 
sc
al
e;
 F
EV
1 
=
 fo
rc
ed
 e
xp
ira
to
ry
 v
ol
um
e;
 F
V
C 
= 
fo
rc
ed
 v
ita
l c
ap
ac
ity
; S
E 
= 
sta
nd
ar
d 
er
ro
r.
a M
od
el
 1
: G
en
er
al
 li
ne
ar
 m
od
el
 a
dju
ste
d f
or 
ag
e, 
he
igh
t, a
nd
 ra
ce.
b M
od
el
 2
: G
en
er
al
 li
ne
ar
 m
od
el
 a
dju
ste
d f
or 
Mo
de
l 1
 va
ria
ble
s p
lus
 sm
ok
ing
 st
atu
s, l
ife
tim
e p
ack
 ye
ars
, a
bd
om
ina
l h
eig
ht,
 ed
uc
ati
on
, a
nd
 se
rum
 be
ta 
cry
pto
xa
nth
in.
d F
EV
1 
an
d 
FE
V
1%
 w
er
e 
al
so
 a
dju
ste
d f
or 
eo
sin
op
hil
 co
un
t.
e F
EV
1%
 a
nd
 F
V
C%
 w
er
e 
an
al
yz
ed
 w
ith
ou
t a
dju
stm
en
ts 
for
 ag
e, 
he
igh
t, a
nd
 ra
ce.
f P
-
v
al
ue
s r
ep
re
se
nt
 m
ul
tip
lic
at
iv
e 
in
te
ra
ct
io
n 
te
rm
s f
or
 se
x 
an
d 
CE
S-
D
 sc
or
e.
Psychosom Med. Author manuscript; available in PMC 2014 October 01.
